Prestige Consumer Healthcare Inc. (FRA:PBV)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.86B -29.9% |
| Revenue (ttm) | 967.11M -1.4% |
| Net Income | 150.56M -19.2% |
| EPS | 3.13 -16.1% |
| Shares Out | n/a |
| PE Ratio | 12.34 |
| Forward PE | 9.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 40.00 |
| Previous Close | 39.60 |
| Day's Range | 39.40 - 40.00 |
| 52-Week Range | 38.00 - 60.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About FRA:PBV
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mo... [Read more]
Financial Performance
In fiscal year 2026, FRA:PBV's revenue was $1.09 billion, a decrease of -4.31% compared to the previous year's $1.14 billion. Earnings were $190.30 million, a decrease of -11.32%.
Financial numbers in USD Financial StatementsNews
Prestige Consumer Healthcare Transcript: Barclays 19th Annual Global Consumer Conference
Recent acquisitions have expanded the portfolio and international reach, with Breathe Right and LaCorium Health expected to drive growth. Clear Eyes recovery and integration of new brands are key near-term priorities, while the company targets 10% sales growth and $900M free cash flow over three years.
Prestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference
TARRYTOWN, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that Ron Lombardi, Chairman, President, & CEO and Christine Sacco, CFO and COO will par...
Football Stress May Be Following Fans to Bed, According to the Inaugural DenTek® Football Stress Test
National survey commissioned by DenTek, the #1 OTC dental guard brand for nighttime teeth grinding, finds nearly 8 in 10 football fans keep thinking about the game after it ends, with many reporting s...
Prestige Consumer Healthcare Transcript: Canaccord Genuity's 46th Annual Growth Conference
A consistent three-pillar strategy drives growth through brand investment, disciplined M&A, and strong financial management. Recent acquisitions (Breathe Right, LaCorium) are expected to accelerate international expansion and free cash flow, while innovation and e-commerce fuel organic growth.
Prestige Consumer Healthcare Earnings Call Transcript: Q1 2027
Q1 revenue grew 6.5% year-over-year, driven by strong GI and skincare brands, and two acquisitions are expected to add over 20% to annualized revenue. Adjusted EPS and free cash flow reached record levels, with updated guidance reflecting acquisition contributions and continued organic growth.
Prestige Consumer Healthcare Earnings release: Q1 2027
Prestige Consumer Healthcare released its Q1 2027 earnings on August 6, 2026, summarizing the period's financial results.
Prestige Consumer Healthcare Quarterly report: Q1 2027
Prestige Consumer Healthcare has published its Q1 2027 quarterly earnings report on August 6, 2026.
Prestige Consumer Healthcare Slides: Q1 2027
Prestige Consumer Healthcare has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 6, 2026.
Prestige Consumer Healthcare Inc. Reports Fiscal 2027 First Quarter Results
TARRYTOWN, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter fiscal 2027 ended June 30, 2026.
Prestige Consumer Healthcare Inc. Completes Acquisition of LaCorium Health, Prices $400 Million Senior Notes Offering, and Announces First Quarter Fiscal 2027 Earnings Results Date
TARRYTOWN, N.Y., July 06, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) (“Prestige”) today announced that it has closed the previously announced acquisition of LaCorium Health ...
Prestige Consumer Healthcare Inc. Announces Offering of $400 Million Senior Notes
TARRYTOWN, N.Y., June 30, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE: PBH) (the “Company”) announced today that its wholly-owned subsidiary, Prestige Brands, Inc. (“Prestige Bran...
Prestige Consumer Healthcare Proxy statement: Proxy filing
Prestige Consumer Healthcare filed a proxy statement on June 29, 2026, providing details for shareholder voting and corporate governance matters.
Prestige Consumer Healthcare Inc. (PBH) Clear Eyes® and Pillar5 Problems Drive Stock Lower, HBSS Investigating
SAN FRANCISCO, June 25, 2026 /PRNewswire/ -- Investors in Prestige Consumer Healthcare (NYSE: PBH) saw the price of their shares fall over 11% on May 14, 2026 after the company revealed significant re...
Prestige Consumer Healthcare Inc Completes Acquisition of Breathe Right®
TARRYTOWN, N.Y., June 15, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) (“Prestige”) today announced that it has closed the previously announced acquisition of the Breathe Righ...
Prestige Consumer Healthcare Transcript: Oppenheimer 26th Annual Consumer Growth and E-Commerce Conference
The session highlighted a disciplined strategy focused on brand leadership, stable growth, and capital allocation, with recent major acquisitions (Breathe Right, LaCorium Health) expected to drive above-average growth. Consumer shifts favor mass and e-commerce, while operational improvements and international expansion underpin a positive outlook.
Prestige Consumer Healthcare Inc. to Participate in the Oppenheimer Annual Consumer Growth and E-Commerce Conference
TARRYTOWN, N.Y., June 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will participate in a fireside chat at the Oppenheimer 26th Annual Consumer Grow...
Prestige Consumer price target lowered to $72 from $86 at Canaccord
Canaccord lowered the firm’s price target on Prestige Consumer (PBH) to $72 from $86 and keeps a Buy rating on the shares. The firm updated its model following its Q4…
Prestige Consumer falls -14.0%
Prestige Consumer (PBH) is down -14.0%, or -$7.25 to $44.56.
Oppenheimer downgrades Prestige Consumer following weaker results, guidance
As previously reported, Oppenheimer analyst Rupesh Parikh downgraded Prestige Consumer (PBH) to Perform from Outperform following the company’s softer than expected Q4 results and weaker initial FY26 ...
Prestige Consumer Healthcare Earnings Call Transcript: Q4 2026
Fiscal 2026 saw a 4% revenue decline due to eye care supply issues and global disruptions, but GI and women's health brands performed well. Fiscal 2027 guidance anticipates 1%-3% organic growth, stable margins, and strong free cash flow, with pending acquisitions expected to drive future growth.
Prestige Consumer Healthcare Earnings release: Q4 2026
Prestige Consumer Healthcare released its Q4 2026 earnings on May 14, 2026, summarizing the period's financial results.
Prestige Consumer Healthcare Slides: Q4 2026
Prestige Consumer Healthcare has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 14, 2026.
Prestige Consumer Healthcare Annual report: Q4 2026
Prestige Consumer Healthcare has published its Q4 2026 annual report on May 14, 2026.
Prestige Consumer downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Prestige Consumer (PBH) to Perform from Outperform.
Prestige Consumer Healthcare Inc. Reports Fiscal 2026 Results, Announces Acquisition of LaCorium Health
TARRYTOWN, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2026.